within Pharmacolibrary.Drugs.ATC.J;

model J05AP06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.201,
    Cl             = 5.033333333333333,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.194,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0095,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Asunaprevir is a direct-acting antiviral drug that acts as an NS3/4A protease inhibitor and was developed for the treatment of chronic hepatitis C virus (HCV) infection, particularly for genotype 1. It has been used in combination therapy (e.g., with daclatasvir). Although once approved in some countries such as Japan, it is not widely used today due to the availability of newer, more effective antiviral agents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects, after oral administration.</p><h4>References</h4><ol><li><p>Eley, T, et al., &amp; Bertz, RJ (2015). Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions. <i>Clinical pharmacokinetics</i> 54(12) 1205–1222. DOI:<a href=&quot;https://doi.org/10.1007/s40262-015-0299-6&quot;>10.1007/s40262-015-0299-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26177803/&quot;>https://pubmed.ncbi.nlm.nih.gov/26177803</a></p></li><li><p>Osawa, M, et al., &amp; Garimella, T (2019). Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects. <i>Clinical pharmacology in drug development</i> 8(6) 802–817. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.649&quot;>10.1002/cpdd.649</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30629858/&quot;>https://pubmed.ncbi.nlm.nih.gov/30629858</a></p></li><li><p>Eley, T, et al., &amp; Bertz, RJ (2017). Asunaprevir: An HCV Protease Inhibitor With Preferential Liver Distribution. <i>Clinical pharmacology in drug development</i> 6(2) 195–200. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.315&quot;>10.1002/cpdd.315</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28263460/&quot;>https://pubmed.ncbi.nlm.nih.gov/28263460</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AP06;
